T1	Participants 44 109	children previously randomly assigned to intrathecal methotrexate
T2	Participants 172 211	childhood acute lymphoblastic leukemia.
T3	Participants 241 436	children with acute lymphoblastic leukemia (ALL), CNS prophylaxis consists of either intrathecal (IT) methotrexate or triple IT therapy (ie, methotrexate with both cytarabine and hydrocortisone).
T4	Participants 577 861	171 children with standard-risk ALL, age 1 to 9.99 years at diagnosis, previously randomly assigned to IT methotrexate (n = 82) or to triple IT therapy (n = 89) on CCG 1952, underwent neurocognitive evaluation by a licensed psychologist at a mean of 5.9 years after random assignment.
T5	Participants 870 907	Patients who received IT methotrexate
T6	Participants 1141 1187	19.5% of children in the IT methotrexate group
T7	Participants 1572 1596	sex or age at diagnosis.
